Open AccessMicrophysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Author(s) -
Passley Hargrove-Grimes,
Lucie A. Low,
Danilo A. Tagle
Publication year - 2021
Publication title -
cells tissues organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.662
H-Index - 82
ISSN - 1422-6405
DOI - 10.1159/000517422
Subject(s) - stakeholder , business , pharmaceutical industry , drug development , knowledge management , process management , microbiology and biotechnology , drug , pharmacology , computer science , public relations , medicine , biology , political science
Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel in vitro models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.